Dry Eye is more than an inconvenience. Dry Eye is a disease.

Many people suffer for years from the discomfort and pain of Dry Eye Disease Most try various products to manage their disease, and while many of the Over-The-Counter products can provide relief, it is just temporary symptom relief.

Meibomian Gland Dysfunction (MGD) is a leading cause of Dry Eye Disease.1 Dry Eye Disease is rarely due to a lack of the watery part of your tears. 86% of dry eye patients have MGD.



What is Meibomian Gland Disfunction (MGD)?

Meibomian Gland Dysfunction is a progressive disease of the ocular surface. Long term, failure to treat MGD can lead to chronic discomfort and degradation of vision, significantly impacting quality of life.

Healthy Meibomian glands that line your upper and lower eyelids secrete oil with every blink. Your Meibomian glands produce the oily part of the tear film needed to protect the surface of your eye by preventing the evaporation of the watery part of your tears. When this function is not working well, your eyes may feel dry. Keeping the function and structure of your Meibomian glands healthy before you become symptomatic is key, as MGD progresses over time.


What causes MGD?

MGD is caused by anatomical changes in the Meibomian glands If left untreated, MGD can become progressively worse over time.

Conditions that can contribute to MGD:


Dry Eyes? Don’t just treat your symptoms, Treat the Cause and MOVE FORWARD with MGD treatment with TearScience® LipiFlow®

For patients with MGD, TearScience® LipiFlow® significantly improves gland secretions and ocular surface symptoms including dry eye and less frequent or blurry vision.

  • The treatment is non-invasive procedure performed in the comfort of your doctor’s office, only takes 12 minutes and can have long-lasting results
  • After initial anesthetic drops, no drugs required for TearScience® LipiFlow® treatment
  • Long-lasting results—many can see the continued benefit up to 12 months
  • 400,000 treatments worldwide—and growing

Just 1 treatment increases mean gland secretion 3-fold and reduces more than 50% dry eye symptoms.

Treatment also increased patient comfortable contact lens wear time by approximately 4 hours on average per day.

TearScience® LipiFlow® treatment prior to cataract surgery improves mean dry eye symptoms and vision-related function scores post-surgery.


Choose TearScience® LipiFlow®.

Because Eye Health Starts at the Surface.


REFERENCES:
1. Craig JP, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017 Jul; 15(3): 276-283
2. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472-478.
3. Xiao J et al. Functional and Morphological Evaluation of Meibomian Glands in the Assessment of Meibomian Gland Dysfunction Subtype and severity. Am J Ophthalmol. 2020;209:160-67.; Geerling G et al. Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction – Proceedings of the OCEAN group meeting. The Ocular Surface. 2017;15:179-92; Ye F,at el. Objective assessment of tear-film quality dynamics in patients with meibomian gland dysfunction and aqueous-deficient dry eye optical quality changes in different dry eye subtypes. Indian Journal of Ophthalmology. 2019;67(5):599-603
4. Lane SS et al. A New System, the TearScience® LipiFlow®, for the Treatment of Meibomian Gland Dysfunction (MGD). Cornea. 2012;31(4):396-404. For illustrative purposes only. This content is presented for educational purposes only. JJSV Surgical Vision, Inc. does not engage in the practice of medicine and any clinical tips within this content are not a substitute for appropriate medical education and training or for the exercise of independent medical judgment. Each medical situation should be considered unique to each patient and all treatments individualized accordingly based on the respective physician’s medical judgment. JJSV Surgical Vision, Inc. does not (1) warranty the accuracy or completeness of any of the clinical tips, or (2) endorse or recommend any technique.
5. Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthalmol. 2016; 10: 1385-1396
6. TearScience® LipiFlow® IFU United States
7. Data on file.
8. Blackie CA et al. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthalmol. 2016; 10: 1385-1396.
9. Blackie CA, et al. A single vectored thermal pulsation treatment for meibomian gland dysfunction increases mean comfortable contact lens wearing time by approximately 4 hours per day. Clin Ophthalmol. 2018;12:169-183.
10. Data on file, 2018 (NCT01808560). Pilot study for treatment of meibomian gland dysfunction (MGD) prior to cataract surgery. Accessed from: https://clinicaltrials.gov/show/NCT1808560.

Content of courtesy of Johnson & Johnson Surgical Vision Inc.